Baseline Neutrophil-to-Lymphocyte Ratio and Efficacy of SGLT2 Inhibition with Empagliflozin on Cardiac Remodelling
Authors' conclusion
Empagliflozin treatment is associated with consistent reductions in LVMi in patients with T2D and CAD independent of baseline NLR.
Study context
- Population
- Patients with T2DM and coronary artery disease (CAD)
- Participants
- 97 patients
- Comparison
- Empagliflozin vs placebo, by baseline neutrophil-to-lymphocyte ratio (NLR)
- Primary endpoint
- Change in LV mass indexed to body surface area (LVMi) by CMR
- Follow-up
- 6 months
Methodological detailssubgroup analysis by baseline NLR
- Subgroup analysis by baseline NLR
Primary result
As reported in the abstract
Change in LVMi, by baseline NLR
Empagliflozin vs PlaceboAdjusted difference, g/m2 (95% CI)P value
NLR < 2
−2.98(−6.18 to 0.22)
P = 0.067NLR ≥ 2
−4.43(−8.50 to −1.11)
Further findings
Baseline LV structure by NLR
- Elevated baseline NLR associated with higher LVMi and LV end-diastolic volume index than lower NLR
Original publication
Baseline Neutrophil-to-Lymphocyte Ratio and Efficacy of SGLT2 Inhibition with Empagliflozin on Cardiac Remodelling. ESC Heart Fail. Published 10 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →